# Cero Therapeutics Holdings, Inc.: overview CERO · OTC · CIK 1870404 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cero.md) · [Financials](/companies/cero/financials.md) · [Filings](/companies/cero/filings.md) · [Insiders](/companies/cero/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(302.32)](/filings/0001213900-25-079898.md) | [(170.22)](/filings/0001213900-25-112619.md) | [(31.82)](/filings/0001213900-26-057753.md) | [(61.71)](/filings/0001213900-26-090030.md) | [(9.10)](/filings/0001213900-25-112619.md) | not reported | [(0.20)](/filings/0001213900-26-057753.md) | [(0.70)](/filings/0001213900-26-090030.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(1248.64)](/filings/0001213900-25-032134.md) | not reported | | Free cash flow | $ | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cero/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $4 | 2,500 | | Unchanged | ## Recent filings [All 443 filings](/companies/cero/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-07 | 12:30 ET | [8-K](/filings/0001213900-26-107410.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-107410 | | 2026-08-31 | 20:52 ET | [8-K](/filings/0001213900-26-095776.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-095776 | | 2026-08-14 | 20:06 ET | [10-Q](/filings/0001213900-26-090030.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090030 | | 2026-07-17 | 20:37 ET | [8-K](/filings/0001213900-26-079207.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-079207 | | 2026-06-26 | 20:05 ET | [8-K](/filings/0001213900-26-072602.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-072602 | | 2026-05-29 | 20:05 ET | [8-K](/filings/0001213900-26-062802.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-062802 | | 2026-05-15 | 20:12 ET | [10-Q](/filings/0001213900-26-057753.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057753 | | 2026-05-01 | 20:10 ET | [8-K](/filings/0001213900-26-050951.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-050951 | | 2026-04-30 | 20:34 ET | [10-K/A](/filings/0001213900-26-050302.md) | Annual report, amended, period 2025-12-31 | 0001213900-26-050302 | | 2026-04-15 | 20:05 ET | [10-K](/filings/0001213900-26-044040.md) | Annual report, period 2025-12-31 | 0001213900-26-044040 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-044040.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1870404 - Tickers: CERO, CEROW - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.